Cipher Pharmaceuticals (CPH) Hits New 52-Week Low at $2.01
Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) shares hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as C$2.01 and last traded at C$2.04, with a volume of 65371 shares trading hands. The stock had previously closed at C$2.14.
Separately, TD Securities raised shares of Cipher Pharmaceuticals from a “hold” rating to a “buy” rating and set a C$4.25 target price on the stock in a research note on Monday, August 13th.
The company has a debt-to-equity ratio of 87.03, a quick ratio of 1.19 and a current ratio of 1.27.
TRADEMARK VIOLATION NOTICE: “Cipher Pharmaceuticals (CPH) Hits New 52-Week Low at $2.01” was first posted by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.dailypolitical.com/2018/11/10/cipher-pharmaceuticals-cph-hits-new-52-week-low-at-2-01.html.
About Cipher Pharmaceuticals (TSE:CPH)
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company offers EPURIS (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; CONZIP/DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain; and Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne in patients.
Recommended Story: Consumer behavior in bull markets
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.